Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 596

1.

Lifetime Psychotic Symptoms, Subthreshold Depression and Cognitive Impairment as Barriers to Functional Recovery in Patients with Bipolar Disorder.

Bonnín CM, Jiménez E, Solé B, Torrent C, Radua J, Reinares M, Grande I, Ruíz V, Sánchez-Moreno J, Martínez-Arán A, Vieta E.

J Clin Med. 2019 Jul 18;8(7). pii: E1046. doi: 10.3390/jcm8071046.

2.

Adverse outcomes during pregnancy and major congenital malformations in infants of patients with bipolar and schizoaffective disorders treated with antiepileptic drugs: A systematic review.

Giménez A, Pacchiarotti I, Gil J, Murru A, Gomes SP, Pinzón JE, Anmella G, Gómez-Ramiro M, Verdolini N, Valentí M, Goikolea JM, Vieta E.

Psychiatr Pol. 2019 Apr 30;53(2):223-244. doi: 10.12740/PP/105906. Epub 2019 Apr 30. English, Polish.

3.

Completed suicide in bipolar disorder patients: A cohort study after first hospitalization.

Plans L, Nieto E, Benabarre A, Vieta E.

J Affect Disord. 2019 Jul 5;257:340-344. doi: 10.1016/j.jad.2019.07.048. [Epub ahead of print]

PMID:
31302523
4.

Neurocognitive endophenotypes in schizophrenia and bipolar disorder: A systematic review of longitudinal family studies.

Luperdi SC, Tabarés-Seisdedos R, Livianos L, Vieta E, Cuesta MJ, Balanzá-Martínez V.

Schizophr Res. 2019 Jul 1. pii: S0920-9964(19)30235-X. doi: 10.1016/j.schres.2019.06.014. [Epub ahead of print] Review.

PMID:
31272906
5.

A 12-month prospective study on the time to hospitalization and clinical management of a cohort of bipolar type I and schizoaffective bipolar patients.

Murru A, Verdolini N, Anmella G, Pacchiarotti I, Samalin L, Aedo A, Undurraga J, Goikolea JM, Amann BL, Carvalho AF, Vieta E.

Eur Psychiatry. 2019 Jun 27;61:1-8. doi: 10.1016/j.eurpsy.2019.06.001. [Epub ahead of print]

PMID:
31255957
6.

Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A.

Eur Neuropsychopharmacol. 2019 Jun 26. pii: S0924-977X(19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub ahead of print] Review.

PMID:
31255396
7.

Effects of electroconvulsive therapy in the systemic inflammatory balance of patients with severe mental disorder.

Bioque M, Mac-Dowell KS, Meseguer A, Macau E, Valero R, Vieta E, Leza JC, Bernardo M.

Psychiatry Clin Neurosci. 2019 Jun 28. doi: 10.1111/pcn.12906. [Epub ahead of print]

PMID:
31250493
8.

Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis.

Perugi G, Pacchiarotti I, Mainardi C, Verdolini N, Menculini G, Barbuti M, Angst J, Azorin JM, Bowden CL, Mosolov S, Young AH, Vieta E; BRIDGE-II-MIX Study Group.

Eur Neuropsychopharmacol. 2019 Jul;29(7):825-834. doi: 10.1016/j.euroneuro.2019.06.001. Epub 2019 Jun 18.

PMID:
31227264
9.

Food craving and consumption evolution in patients starting treatment with clozapine.

Garriga M, Mallorquí A, Serrano L, Ríos J, Salamero M, Parellada E, Gómez-Ramiro M, Oliveira C, Amoretti S, Vieta E, Bernardo M, García-Rizo C.

Psychopharmacology (Berl). 2019 Jun 13. doi: 10.1007/s00213-019-05291-3. [Epub ahead of print]

PMID:
31197435
10.

Relationships between recurrence and polarity in major depressive disorders: Pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts.

Barbuti M, Mazzarini L, Vieta E, Azorin JM, Angst J, Bowden CL, Mosolov S, Young AH, Perugi G; BRIDGE-II-Mix Study Group.

J Affect Disord. 2019 Jun 4;256:250-258. doi: 10.1016/j.jad.2019.06.005. [Epub ahead of print]

PMID:
31195243
11.

Association of Anorexia Nervosa With Risk of Cancer: A Systematic Review and Meta-analysis.

Catalá-López F, Forés-Martos J, Driver JA, Page MJ, Hutton B, Ridao M, Alonso-Arroyo A, Macías Saint-Gerons D, Gènova-Maleras R, Valderas JM, Vieta E, Valencia A, Tabarés-Seisdedos R.

JAMA Netw Open. 2019 Jun 5;2(6):e195313. doi: 10.1001/jamanetworkopen.2019.5313.

12.

Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses.

Fullana MA, Tortella-Feliu M, Fernández de la Cruz L, Chamorro J, Pérez-Vigil A, Ioannidis JPA, Solanes A, Guardiola M, Almodóvar C, Miranda-Olivos R, Ramella-Cravaro V, Vilar A, Reichenberg A, Mataix-Cols D, Vieta E, Fusar-Poli P, Fatjó-Vilas M, Radua J.

Psychol Med. 2019 Jun 7:1-16. doi: 10.1017/S0033291719001247. [Epub ahead of print]

PMID:
31172897
13.

Pharmacotherapy for the peripartum management of bipolar disorder.

Belzeaux R, Sanguinetti C, Murru A, Verdolini N, Pacchiarotti I, Hidalgo-Mazzei D, Cohen L, Anmella G, Barbuti M, Vieta E, Llorca PM, Samalin L.

Expert Opin Pharmacother. 2019 Jun 10:1-11. doi: 10.1080/14656566.2019.1626826. [Epub ahead of print]

PMID:
31159601
14.

The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state?

Brancati GE, Vieta E, Azorin JM, Angst J, Bowden CL, Mosolov S, Young AH, Perugi G; BRIDGE–II–Mix Study Group.

J Psychiatr Res. 2019 Aug;115:151-157. doi: 10.1016/j.jpsychires.2019.05.014. Epub 2019 May 14.

PMID:
31132693
15.

Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study.

Escarti MJ, Garcia-Marti G, Sanz-Requena R, Marti-Bonmatí L, Cabrera B, Vieta E, Lobo A, Castro-Fornieles J, González-Pinto A, Cortizo R, Pina-Camacho L, Parellada M, Bernardo M, Sanjuan J; PEPs Group.

Schizophr Res. 2019 May 18. pii: S0920-9964(19)30162-8. doi: 10.1016/j.schres.2019.05.001. [Epub ahead of print]

PMID:
31113747
16.

What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.

Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, Kupka RW, Zarate C, Nielsen RE, Baldessarini RJ, Severus E; ISBD/IGSLI Task Force on the treatment with lithium.

Bipolar Disord. 2019 May 21. doi: 10.1111/bdi.12805. [Epub ahead of print] Review.

PMID:
31112628
17.

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.

Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.

PMID:
31109201
18.

One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry.

Bernardo M, Cabrera B, Arango C, Bioque M, Castro-Fornieles J, Cuesta MJ, Lafuente A, Parellada M, Saiz-Ruiz J, Vieta E.

Rev Psiquiatr Salud Ment. 2019 Jul - Sep;12(3):135-140. doi: 10.1016/j.rpsm.2019.03.001. Epub 2019 May 16. English, Spanish. No abstract available.

PMID:
31103407
19.

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.

Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A.

Int Clin Psychopharmacol. 2019 Jul;34(4):153-160. doi: 10.1097/YIC.0000000000000271.

20.

Improving Functioning, Quality of Life, and Well-being in Patients With Bipolar Disorder.

Bonnín CDM, Reinares M, Martínez-Arán A, Jiménez E, Sánchez-Moreno J, Solé B, Montejo L, Vieta E.

Int J Neuropsychopharmacol. 2019 Apr 19. pii: pyz018. doi: 10.1093/ijnp/pyz018. [Epub ahead of print]

PMID:
31093646

Supplemental Content

Loading ...
Support Center